Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsShortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, Rao SV, Nanna MG. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. American Heart Journal 2022, 251: 101-114. PMID: 35654162, PMCID: PMC10904033, DOI: 10.1016/j.ahj.2022.05.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeDrug Therapy, CombinationDrug-Eluting StentsHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeConceptsMonths of DAPTHazard ratioIschemic eventsDuration of DAPTSelect patient characteristicsDual antiplatelet therapyAcute coronary syndromeCoronary artery lesionsPercutaneous coronary interventionConfidence intervalsAssociation of outcomesRandom-effects modelComprehensive literature searchMeta-regression analysisMajor bleedingAntiplatelet therapyCoronary syndromeArtery lesionsCoronary interventionControlled TrialsPatient characteristicsPrespecified outcomesGreater proportionSimilar efficacySystematic review